Anaplastic Astrocytoma
📧 Sign up to get email alerts when something new happens for Anaplastic Astrocytoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-05-08FDA Approved: TEMOZOLOMIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's Original Application for temozolomide (generic temozolomide), authorizing its marketed generic pro…
-
CLINICAL_TRIALS trial_result · 2015-04-22Clinical Trial Update: Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) [Phase 1]
Completed Phase 1 study evaluating super-selective intraarterial intracranial infusion of bevacizumab (Avastin) for glioblastoma and anaplas…
-
FDA approval · 2015-04-02FDA Approved: TEMODAR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approves a supplemental application for TEMODAR (temozolomide) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2015-04-02FDA Approved: TEMODAR — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Temodar (temozolomide) from Merck, resulting in an updated labeling and/or indication for th…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms [Phase 2]
A Phase II trial of Carmustine, Streptozocin, and Mercaptopurine for refractory or recurrent brain neoplasms has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-01-07Clinical Trial Update: A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas [Phase 1]
This report covers a Phase I trial of nanoliposomal irinotecan (NL-CPT-11) in patients with recurrent high-grade gliomas, completed to evalu…
-
FDA approval · 2015-01-05FDA Approved: TEMOZOLOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application to authorize a generic version of temozolomide.
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors [Phase 1]
This Phase 1 trial evaluated the combination of RO4929097, a gamma-secretase inhibitor, with Cediranib maleate in adults with advanced solid…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma [Phase 1]
Phase 1 trial evaluating high-dose vorinostat with fractionated SBRT in patients with recurrent glioma; the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-11-14Clinical Trial Update: Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma [Phase 1, Phase 2]
The clinical trial evaluating interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma has completed Phase 1 and Phase …
-
CLINICAL_TRIALS trial_result · 2014-11-04Clinical Trial Update: Sorafenib in Newly Diagnosed High Grade Glioma [Phase 1]
Phase 1 trial update evaluating sorafenib in newly diagnosed high-grade glioma, including glioblastoma, gliosarcoma, and various anaplastic …
-
CLINICAL_TRIALS trial_result · 2014-08-22Clinical Trial Update: Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma [Phase 3]
A Phase 3 study of AP-12009 in recurrent or refractory anaplastic astrocytoma or secondary glioblastoma was terminated, and results have bee…
-
CLINICAL_TRIALS trial_result · 2014-08-18Clinical Trial Update: BIBF 1120 for Recurrent High-Grade Gliomas [Phase 2]
Phase 2 trial update on BIBF 1120 (nintedanib) for recurrent high-grade gliomas, with the study status now completed and results posted in 2…
-
CLINICAL_TRIALS withdrawal · 2014-06-02Clinical Trial Update: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas [Phase 1]
Phase 1 trial evaluating genetically modified stem cells with Irinotecan hydrochloride for recurrent high-grade gliomas has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-05-30Clinical Trial Update: Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma [Phase 1]
Phase 1 clinical trial assessing aflibercept in combination with radiation therapy and temozolomide in adults with newly diagnosed or recurr…
-
CLINICAL_TRIALS trial_result · 2014-05-30Clinical Trial Update: Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma [Phase 1]
This update covers a Phase 1 trial of sorafenib in patients with recurrent or progressive malignant glioma, including several glioma subtype…
-
FDA approval · 2014-03-20FDA Approved: TEMODAR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Temodar (temozolomide) by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2014-02-20Clinical Trial Update: Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy [Phase 2]
This Phase 2, NCI-sponsored trial evaluated cilengitide in children and adolescents with recurrent or progressive high-grade glioma refracto…
-
CLINICAL_TRIALS trial_result · 2014-02-19Clinical Trial Update: Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma [Phase 1]
Phase 1 study evaluating the safety and potential activity of bevacizumab plus cediranib in patients with metastatic or unresectable solid t…
-
FDA approval · 2014-02-12FDA Approved: TEMOZOLOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a generic temozolomide product under an original ANDA from Sun Pharmaceutical Industries, Inc. Temozolomide is used to treat ma…
-
CLINICAL_TRIALS trial_result · 2013-12-03Clinical Trial Update: Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma [Phase 2]
A Phase IIb trial of AP-12009, a TGF-β2 antisense oligonucleotide, for recurrent or refractory high-grade glioma including glioblastoma and …
-
CLINICAL_TRIALS research · 2013-11-06Clinical Trial Update: Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas [Phase 3]
This is a Phase 3 trial evaluating whether adding photodynamic therapy to standard surgery, radiation therapy, and chemotherapy improves tre…
-
CLINICAL_TRIALS trial_result · 2013-10-25Clinical Trial Update: Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas [Phase 1]
This is a completed Phase I trial evaluating an oral combination of topotecan and temozolomide for malignant gliomas, including glioblastoma…
-
FDA approval · 2013-08-15FDA Approved: GLEOSTINE — Supplemental Application (NextSource Biotechnology, LLC)
The FDA approved a supplemental application for Gleostine (lomustine) submitted by NextSource Biotechnology, LLC.
-
CLINICAL_TRIALS trial_result · 2013-06-14Clinical Trial Update: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer [Phase 2]
Phase 2 trial evaluating bevacizumab to reduce central nervous system side effects after brain radiotherapy in patients with various brain t…